{"id":69166,"date":"2026-07-01T13:55:59","date_gmt":"2026-07-01T05:55:59","guid":{"rendered":"https:\/\/flcube.com\/?p=69166"},"modified":"2026-07-01T13:56:00","modified_gmt":"2026-07-01T05:56:00","slug":"huiyu-pharma-receives-nmpa-clinical-trial-approval-for-hy-1016-extended-release-dienogest-injection-novel-formulation-aims-to-transform-endometriosis-treatment-adherence","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69166","title":{"rendered":"Huiyu Pharma Receives NMPA Clinical Trial Approval for HY-1016 Extended-Release Dienogest Injection \u2013 Novel Formulation Aims to Transform Endometriosis Treatment Adherence"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Sichuan Huiyu Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688553:SHA\">SHA: 688553<\/a>) announced today that it has received <strong>clinical trial approval<\/strong> from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for <strong>HY-1016 extended-release injection<\/strong>, a novel formulation of <strong>dienogest<\/strong> for the treatment of <strong>endometriosis<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The investigational product represents a <strong>Category 2.2 chemical drug<\/strong> filing under China&#8217;s regulatory classification system, featuring a <strong>novel extended-release formulation<\/strong> and <strong>injectable route of administration<\/strong> designed to significantly reduce dosing frequency for patients requiring long-term endometriosis management while maintaining clinical efficacy and safety.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Authority<\/strong><\/td><td>National Medical Products Administration (NMPA), China<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial authorization<\/td><\/tr><tr><td><strong>Product Name<\/strong><\/td><td>HY-1016 extended-release injection<\/td><\/tr><tr><td><strong>Active Ingredient<\/strong><\/td><td>Dienogest<\/td><\/tr><tr><td><strong>Drug Classification<\/strong><\/td><td>Category 2.2 (novel formulation\/novel route of administration)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Endometriosis treatment<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Pre-clinical to Phase I\/II transition<\/td><\/tr><tr><td><strong>Strategic Significance<\/strong><\/td><td>First extended-release injectable dienogest formulation in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-disease-background-amp-current-treatment-landscape\" class=\"wp-block-heading\">Disease Background &amp; Current Treatment Landscape<\/h2>\n\n\n\n<h3 id=\"h-endometriosis-overview\" class=\"wp-block-heading\">Endometriosis Overview<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prevalence:<\/strong> Affects approximately <strong>10% of reproductive-age women<\/strong> globally, with an estimated <strong>50 million patients in China<\/strong><\/li>\n\n\n\n<li><strong>Pathophysiology:<\/strong> Estrogen-dependent inflammatory condition characterized by endometrial-like tissue growth outside the uterus<\/li>\n\n\n\n<li><strong>Clinical Burden:<\/strong> Chronic pelvic pain, infertility, dysmenorrhea, and significant impact on quality of life<\/li>\n\n\n\n<li><strong>Treatment Duration:<\/strong> Requires <strong>long-term continuous therapy<\/strong> often spanning years or decades<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-current-standard-of-care\" class=\"wp-block-heading\">Current Standard of Care<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Line Therapy:<\/strong> <strong>Dienogest<\/strong> \u2013 highly selective progesterone receptor agonist<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Creates low-estrogen, high-progestogen endocrine environment inducing decidualization of endometrial tissue<\/li>\n\n\n\n<li><strong>Efficacy:<\/strong> Proven to reduce endometriotic lesions and alleviate symptoms<\/li>\n\n\n\n<li><strong>Limitations:<\/strong><\/li>\n\n\n\n<li><strong>Daily oral dosing<\/strong> requirement leading to adherence challenges<\/li>\n\n\n\n<li><strong>Gastrointestinal side effects<\/strong> from oral administration<\/li>\n\n\n\n<li><strong>Peak-trough fluctuations<\/strong> in drug exposure affecting tolerability<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-hy-1016-next-generation-endometriosis-therapy\" class=\"wp-block-heading\">HY-1016: Next-Generation Endometriosis Therapy<\/h2>\n\n\n\n<h3 id=\"h-product-innovation\" class=\"wp-block-heading\">Product Innovation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Formulation:<\/strong> Extended-release injectable suspension<\/li>\n\n\n\n<li><strong>Dosing Frequency:<\/strong> Significantly reduced vs. daily oral administration (specific interval TBD based on clinical data)<\/li>\n\n\n\n<li><strong>Route of Administration:<\/strong> Subcutaneous or intramuscular injection<\/li>\n\n\n\n<li><strong>Pharmacokinetic Profile:<\/strong> Sustained therapeutic drug levels with minimized peak-trough fluctuations<\/li>\n\n\n\n<li><strong>Patient Benefits:<\/strong><\/li>\n\n\n\n<li><strong>Improved medication adherence<\/strong> through less frequent dosing<\/li>\n\n\n\n<li><strong>Enhanced convenience<\/strong> eliminating daily pill burden<\/li>\n\n\n\n<li><strong>Potentially improved tolerability<\/strong> avoiding first-pass metabolism<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-clinical-development-strategy\" class=\"wp-block-heading\">Clinical Development Strategy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Primary Objectives:<\/strong> Demonstrate non-inferiority in efficacy vs. oral dienogest<\/li>\n\n\n\n<li><strong>Secondary Endpoints:<\/strong> Superior adherence rates, improved quality of life measures, favorable safety profile<\/li>\n\n\n\n<li><strong>Target Population:<\/strong> Women requiring long-term endometriosis management<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> First-to-market extended-release dienogest formulation in China<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-opportunity-amp-commercial-implications\" class=\"wp-block-heading\">Market Opportunity &amp; Commercial Implications<\/h2>\n\n\n\n<h3 id=\"h-chinese-endometriosis-market\" class=\"wp-block-heading\">Chinese Endometriosis Market<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Size:<\/strong> Estimated <strong>USD 800 million\u20131.2 billion<\/strong> annual market opportunity<\/li>\n\n\n\n<li><strong>Treatment Gap:<\/strong> Significant unmet need for improved adherence solutions<\/li>\n\n\n\n<li><strong>Reimbursement Environment:<\/strong> Favorable coverage for innovative women&#8217;s health therapeutics<\/li>\n\n\n\n<li><strong>Patient Demographics:<\/strong> Large addressable population of working-age women seeking convenient treatment options<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-competitive-positioning\" class=\"wp-block-heading\">Competitive Positioning<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover Advantage:<\/strong> Potential to establish category leadership in extended-release endometriosis therapies<\/li>\n\n\n\n<li><strong>Premium Pricing:<\/strong> Novel delivery system supports premium reimbursement vs. generic oral dienogest<\/li>\n\n\n\n<li><strong>Brand Differentiation:<\/strong> Addresses key patient pain points around daily medication burden<\/li>\n\n\n\n<li><strong>Physician Adoption:<\/strong> Aligns with growing preference for long-acting reversible treatments in chronic conditions<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-strategic-value-for-huiyu-pharma\" class=\"wp-block-heading\">Strategic Value for Huiyu Pharma<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Diversification:<\/strong> Expands beyond existing therapeutic areas into high-value women&#8217;s health segment<\/li>\n\n\n\n<li><strong>Innovation Credentials:<\/strong> Demonstrates advanced formulation capabilities in complex drug delivery<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Peak annual sales potential of <strong>RMB 500 million\u2013800 million<\/strong> (USD 70\u2013110 million) if successful<\/li>\n\n\n\n<li><strong>Global Licensing Potential:<\/strong> Platform technology could support international partnerships<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-development-timeline-amp-next-steps\" class=\"wp-block-heading\">Development Timeline &amp; Next Steps<\/h2>\n\n\n\n<h3 id=\"h-clinical-pathway\" class=\"wp-block-heading\">Clinical Pathway<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase I:<\/strong> Pharmacokinetic and safety studies (initiating Q3 2026)<\/li>\n\n\n\n<li><strong>Phase II:<\/strong> Dose-finding and preliminary efficacy assessment (expected 2027)<\/li>\n\n\n\n<li><strong>Phase III:<\/strong> Pivotal efficacy and safety trials vs. standard of care (expected 2028\u20132029)<\/li>\n\n\n\n<li><strong>NDA Submission:<\/strong> Targeting 2030 for potential market launch<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-regulatory-strategy\" class=\"wp-block-heading\">Regulatory Strategy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China First:<\/strong> Leveraging domestic regulatory expertise and market knowledge<\/li>\n\n\n\n<li><strong>International Expansion:<\/strong> Potential global filings following Chinese approval<\/li>\n\n\n\n<li><strong>Patent Protection:<\/strong> Comprehensive IP strategy covering formulation and manufacturing processes<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-investment-considerations\" class=\"wp-block-heading\">Investment Considerations<\/h2>\n\n\n\n<h3 id=\"h-risk-factors\" class=\"wp-block-heading\">Risk Factors<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Development Risk:<\/strong> Typical Phase I\u2013III attrition rates apply<\/li>\n\n\n\n<li><strong>Manufacturing Complexity:<\/strong> Extended-release formulations require specialized production capabilities<\/li>\n\n\n\n<li><strong>Market Competition:<\/strong> Potential entry of other long-acting endometriosis therapies<\/li>\n\n\n\n<li><strong>Pricing Pressure:<\/strong> Generic competition in oral dienogest market may impact premium pricing ability<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-success-catalysts\" class=\"wp-block-heading\">Success Catalysts<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Strong Clinical Data:<\/strong> Demonstrated superiority in adherence and quality of life measures<\/li>\n\n\n\n<li><strong>Favorable Reimbursement:<\/strong> Inclusion in national insurance formularies<\/li>\n\n\n\n<li><strong>Physician Education:<\/strong> Effective market development programs highlighting adherence benefits<\/li>\n\n\n\n<li><strong>Patient Advocacy:<\/strong> Strong support from endometriosis patient organizations<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial expectations. Actual outcomes may differ due to risks including clinical trial results, regulatory decisions, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><br><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688553_20260701_UCLK.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688553_20260701_UCLK.\"><\/object><a id=\"wp-block-file--media-df517c3b-2b9c-4add-92bc-e4c09b55e43c\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688553_20260701_UCLK.pdf\">688553_20260701_UCLK<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688553_20260701_UCLK.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-df517c3b-2b9c-4add-92bc-e4c09b55e43c\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553) announced today that it has received clinical trial&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,400,1198],"class_list":["post-69166","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-huiyu-pharmaceutical","tag-sha-688553"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Huiyu Pharma Receives NMPA Clinical Trial Approval for HY-1016 Extended-Release Dienogest Injection \u2013 Novel Formulation Aims to Transform Endometriosis Treatment Adherence - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553) announced today that it has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for HY-1016 extended-release injection, a novel formulation of dienogest for the treatment of endometriosis.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69166\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Huiyu Pharma Receives NMPA Clinical Trial Approval for HY-1016 Extended-Release Dienogest Injection \u2013 Novel Formulation Aims to Transform Endometriosis Treatment Adherence\" \/>\n<meta property=\"og:description\" content=\"Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553) announced today that it has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for HY-1016 extended-release injection, a novel formulation of dienogest for the treatment of endometriosis.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69166\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-01T05:55:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-01T05:56:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69166#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69166\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Huiyu Pharma Receives NMPA Clinical Trial Approval for HY-1016 Extended-Release Dienogest Injection \u2013 Novel Formulation Aims to Transform Endometriosis Treatment Adherence\",\"datePublished\":\"2026-07-01T05:55:59+00:00\",\"dateModified\":\"2026-07-01T05:56:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69166\"},\"wordCount\":709,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Huiyu Pharmaceutical\",\"SHA: 688553\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69166#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69166\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69166\",\"name\":\"Huiyu Pharma Receives NMPA Clinical Trial Approval for HY-1016 Extended-Release Dienogest Injection \u2013 Novel Formulation Aims to Transform Endometriosis Treatment Adherence - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-01T05:55:59+00:00\",\"dateModified\":\"2026-07-01T05:56:00+00:00\",\"description\":\"Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553) announced today that it has received clinical trial approval from China's National Medical Products Administration (NMPA) for HY-1016 extended-release injection, a novel formulation of dienogest for the treatment of endometriosis.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69166#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69166\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69166#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Huiyu Pharma Receives NMPA Clinical Trial Approval for HY-1016 Extended-Release Dienogest Injection \u2013 Novel Formulation Aims to Transform Endometriosis Treatment Adherence\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Huiyu Pharma Receives NMPA Clinical Trial Approval for HY-1016 Extended-Release Dienogest Injection \u2013 Novel Formulation Aims to Transform Endometriosis Treatment Adherence - Insight, China&#039;s Pharmaceutical Industry","description":"Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553) announced today that it has received clinical trial approval from China's National Medical Products Administration (NMPA) for HY-1016 extended-release injection, a novel formulation of dienogest for the treatment of endometriosis.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69166","og_locale":"en_US","og_type":"article","og_title":"Huiyu Pharma Receives NMPA Clinical Trial Approval for HY-1016 Extended-Release Dienogest Injection \u2013 Novel Formulation Aims to Transform Endometriosis Treatment Adherence","og_description":"Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553) announced today that it has received clinical trial approval from China's National Medical Products Administration (NMPA) for HY-1016 extended-release injection, a novel formulation of dienogest for the treatment of endometriosis.","og_url":"https:\/\/flcube.com\/?p=69166","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-01T05:55:59+00:00","article_modified_time":"2026-07-01T05:56:00+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69166#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69166"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Huiyu Pharma Receives NMPA Clinical Trial Approval for HY-1016 Extended-Release Dienogest Injection \u2013 Novel Formulation Aims to Transform Endometriosis Treatment Adherence","datePublished":"2026-07-01T05:55:59+00:00","dateModified":"2026-07-01T05:56:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69166"},"wordCount":709,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Huiyu Pharmaceutical","SHA: 688553"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69166#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69166","url":"https:\/\/flcube.com\/?p=69166","name":"Huiyu Pharma Receives NMPA Clinical Trial Approval for HY-1016 Extended-Release Dienogest Injection \u2013 Novel Formulation Aims to Transform Endometriosis Treatment Adherence - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-01T05:55:59+00:00","dateModified":"2026-07-01T05:56:00+00:00","description":"Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553) announced today that it has received clinical trial approval from China's National Medical Products Administration (NMPA) for HY-1016 extended-release injection, a novel formulation of dienogest for the treatment of endometriosis.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69166#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69166"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69166#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Huiyu Pharma Receives NMPA Clinical Trial Approval for HY-1016 Extended-Release Dienogest Injection \u2013 Novel Formulation Aims to Transform Endometriosis Treatment Adherence"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69166"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69166\/revisions"}],"predecessor-version":[{"id":69168,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69166\/revisions\/69168"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69166"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69166"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}